This issue of Emerging Cancer Therapeutics provides a comprehensive review for practitioners on the current status of melanoma treatment. Due to recent drug approvals and increasing ability to offer combined agents, there are many more treatment options available to melanoma patients than even a few years ago. Especially significant are the recent FDA approval of the immunotherapeutic agent ipilimumab for metastatic melanoma, and new agents targeting the BRAF gene in malignant melanoma. There is also coverage of the most recent data pertaining to surgical management, staging and prevention, and melanoma in children.
Emerging Cancer Therapeutics provides a thorough analysis of key clinical research related to cancer therapeutics, including a discussion and assessment of current evidence, current clinical best practice, and likely near future developments. There is an emphasis throughout on multidisciplinary approaches to the specialty, as well as on quality and outcomes analysis. Emerging Cancer Therapeutics provides authoritative, thorough assessments of advances in therapeutics in all major areas of oncology, both solid and hematologic malignancies, with a focus on advances in medical and biological therapies with emerging clinical impact and encompassing new technologies with implications for management such as molecular imaging.
1. Preventing Melanoma, Barbara Summerer, MD, Sewon Kang, MD, and Timothy Wang, MD, 2. Evolution of the Melanoma Staging System, Rohit R. Sharma, Glen C. Balch, and Charles M. Balch, 3. Less Common Variants of Cutaneous Melanoma, Raymond L. Barnhill and Kapil Gupta, 4. Controversies in the Management of the Regional Node Basin in Cutaneous Melanoma, Ioannis Hatzaras and Julie R. Lange, 5. Adjuvant Therapy for Melanoma, Tara C. Gangadhar and Lynn M. Schuchter, 6. RAF Kinase Inhibitor Therapy in Melanoma, James J. Harding and Paul B. Chapman, 7. Emerging Targets for Melanoma Therapy Besides BRAF, Young Kwang Chae, Sapna P. Patel, andKevin B. Kim, 8. Ipilimumab: The New Frontier of T-Cell Antibodies: A Paradigm Shift in Immuno-Oncology, Steven J. O'Day, 9. Adoptive Cell Transfer Immunotherapy for Patients with Metastatic Melanoma, Crystal J. Hessman, Ashley A. Stewart, Akemi D. Miller, James C. Yang, and Steven A. Rosenberg, 10. Immunotherapies for Metastatic Melanoma, Kevin Conlon, 11. Updated Approach to the Patient with Metastatic Melanoma, Rodabe N. Amaria andRene Gonzalez
About the Guest Editors
William H. Sharfman, MD, Associate Professor of Oncology, Associate Professor of Dermatology, Johns Hopkins School of Medicine
Jame Abraham, MD, FACP, Bonnie Wells Wilson Distingushed Professor and Eminent Scholar, Chief, Section of Hematology-Oncology, and Medical Director, Mary Babb Randolph Cancer Center, West Virginia University